§ References·CJC-1295
Every source, listed.
DOIs and URLs for each citation referenced across the site, in numbered order.
Primary literature and regulatory sources
The numbered references below cover every claim cited on this site. PubMed links are preferred where available; ClinicalTrials.gov links are used for trial-registry entries; the FDA briefing-materials PDFs and the WADA Prohibited List are linked directly to their official locations.
-
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058.
-
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
-
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Plasma half-life characterization of CJC-1295 across single- and multi-dose cohorts (mean t½ 5.8–8.1 days). J Clin Endocrinol Metab. 2006;91(3):799–805.
-
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
-
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–E1294.
-
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–477.
-
ConjuChem Biotechnologies Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov identifier
NCT00267527. Trial terminated October 2006. -
Jetté L, Léger R, Thibaudeau K, et al. Modified GRF(1-29) and the protective amino acid substitutions D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷ — non-DAC variant pharmacokinetics. Characterized in the same Endocrinology 2005 paper as the bioconjugate discovery.
-
Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Combined administration of GHRH and GHRP-6 acts in synergy on growth hormone (GH) release in humans. J Clin Endocrinol Metab. 1990;70(4):975–982.
-
Van Hout MC, Hearne E. Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Subst Use Misuse. 2016;51(1):73–84.
-
Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11–12):647–650.
-
Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fußhöller G, Görgens C, Geyer H, Thevis M. Chromatographic-mass spectrometric analysis of peptidic analytes (2–10 kDa) in doping control urine samples. J Mass Spectrom. 2024;59(2):e4996.
-
Steiger A, Guldner J, Hemmeter U, et al. Growth hormone-releasing hormone (GHRH) and sleep regulation. Psychoneuroendocrinology. 1992;17(2–3):125–137.
-
U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee — CJC-1295 briefing materials. FDA docket
FDA-2024-N-4777. -
U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee meeting — follow-up briefing on GH secretagogue peptides. FDA docket
FDA-2024-N-4777follow-up. -
World Anti-Doping Agency. World Anti-Doping Code International Standard — The 2025 Prohibited List. Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics.
-
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389.
-
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Adverse-event profile in the Phase 1 single- and multi-dose CJC-1295 cohorts: predominantly local injection-site reactions; systemic adverse events uncommon at 30–60 µg/kg. J Clin Endocrinol Metab. 2006;91(3):799–805.
Editorial sourcing standards
Every quantitative claim on this site — half-life numbers, dose values, percentage elevations, trial sample sizes, study durations, adverse event frequencies, and regulatory determinations — traces to a numbered reference above. Where the published literature is ambiguous or incomplete, the site says so rather than filling the gap with secondary or non-peer-reviewed sources.
The site does not cite anonymous forum threads, vendor product pages, research-chemical-channel marketing material, or undated YouTube content. The Van Hout 2016 netnographic analysis [10] is cited because it is a peer-reviewed academic study of online forum behavior, not because the forum content itself is treated as evidence.
Where a primary source is paywalled and a freely accessible companion (PMC version, preprint, or open-access regulatory document) exists, the open version is linked.
Claims about FDA status reference the official FDA Pharmacy Compounding Advisory Committee briefing materials [14][15], not secondary summaries. Claims about WADA status reference the official 2025 Prohibited List [16] directly.